Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
Clinical Trial | By McMurray JJ, Krum H, ATMOSPHERE Committees Investigators.
Cardiac Troponin Elevation in Patients Without a Specific Diagnosis
Original Research | By KM Eggers, T Jernberg, B Lindahl.
BACKGROUND - Cardiac troponin (cTn) elevation is a common finding in acutely admitted patients, even in the absence of acute coronary syndrome. In some of these patients, no etiology of cTn elevation can be identified. The term troponinemia is sometimes used to describe this scenario. OBJECTIVES - This study aimed to investigate the associations of cTn levels with clinical findings and long-term outcome in ...
Contemporary techniques in percutaneous coronary intervention for bifurcation lesions
Review Article | By Collet C, Mizukami T, Grundeken MJ.
Treatment of coronary bifurcation lesions with contemporary state-of-the-art percutaneous coronary intervention (PCI) is still associated with higher rate of adverse cardiovascular events compared to non-bifurcation lesions. Bench testing and virtual computer modeling have increased our understanding of bifurcation PCI guiding refinement in bifurcation techniques. New insights on bifurcation PCI have the potential to further improve clinical outcomes in...
Clinical Trial | By Wang TY, Kaltenbach LA, Cannon CP et al.
IMPORTANCE - Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations. OBJECTIVE - To determine whether removing co-payment barriers increases P2Y12 inhibitor persistence and lo...
Clinical Trial | By Moalem K, Baber U, Mehran R et al.
BACKGROUND - The disruption of dual antiplatelet therapy (DAPT) due to non-compliance or bleeding is known to significantly increase the risk of adverse outcomes after percutaneous coronary intervention (PCI). However, it is currently unknown if there are differences in the predictors and clinical impact of disruption due to non-compliance compared with bleeding. METHODS - The patterns of non-adherence t...
Switching P2Y12-receptor inhibitors in patients with coronary artery disease
Review Article | By Rollini F, Franchi F, Angiolillo DJ.
Dual antiplatelet therapy--the combination of aspirin and a P2Y12-receptor inhibitor--is the cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those undergoing percutaneous coronary intervention. Prasugrel and ticagrelor have more prompt, potent, and predictable antiplatelet effects than those of clopidogrel, and result in reduced ischaemic outcomes in patients with ACS, albeit at the expense of an ...
Clinical Trial | By Valgimigli M, Frigoli E, MATRIX Investigators.
BACKGROUND - The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive manage...